GlobeNewswire

Healthcare Technology Product and Marketing Leader, Gregory Tennant, Joins Inspirata as Chief Strategy and Marketing Officer

Share

With a diverse background in the healthcare market, Greg will work with Inspirata’s senior leadership team on the strategic positioning of the company.

Tampa, FL, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that healthcare technology product and marketing leader, Gregory (Greg) Tennant, has joined Inspirata as Chief Strategy and Marketing Officer, effective December 3, 2018.



Based in the company’s headquarters in Tampa, Florida, Greg is responsible for leading the company’s strategic planning and investments in conjunction with Inspirata’s CEO, Satish Sanan.  Greg is also responsible for driving Inspirata’s go-to-market strategy and overall branding strategy.  Greg is a growth-oriented healthcare technology product and marketing strategist.  He has 8+ years as CEO, has led revenue growth of $525M+ and successfully led multiple companies to market leadership positions.


“Greg has a wealth of experience in strategic planning, brand development and marketing, particularly in the healthcare sector,” says Chairmen and CEO, Satish Sanan. “He has developed and marketed dozens of offerings to the healthcare market, successfully repositioned companies, and has a strong knowledge of healthcare compliance and quality requirements”.

Prior to joining Inspirata, Greg led corporate and product marketing at DrFirst, where he supported multiple sales channels to achieve record company growth and used state-of-the-art digital targeting and outbound sales platforms to launch two mobile solutions.  Greg holds a degree in Economics and Business Management from Cornell University and Executive MBA Certifications from Cornell Johnson School of Management and Duke University Fuquay School of Business.

“Greg’s command of competitive positioning, enterprise technology and the healthcare industry, combined with his impressive abilities in marketing and leadership enable him to provide effective strategies that will further Inspirata’s market leadership”, says Inspirata CEO Satish Sanan.


About Inspirata, Inc.

Inspirata®, Inc. offers the most comprehensive cancer diagnostics workflow solution available for precision diagnosis today. The solution, which employs a unique “solution-as-a-service” business and delivery model, accelerates anatomic and molecular pathology workflows and facilitates whole slide imaging and image analytics, prognostic and predictive assays, remote consultations and tumor boards. This comprehensive solution includes an Enterprise Service Bus (ESB) to help to solve interoperability issues and a Natural Language Processing Engine (NLP) for structuring data. Inspirata amalgamates this structured data into a central multi-institutional and multi-modal big data cancer repository for clinical, research and educational purposes. Its use will extend to physicians, patients, researchers and pharma among others. This comprehensive solution facilitates a modern precision diagnosis to build a strong foundation for precision medicine. For more information, please visit www.inspirata.com or contact info@inspirata.com.


All trademarks used herein are the property of their respective owners.


For further information about Inspirata, please contact:

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Idorsia announces positive results in the second Phase 3 study of daridorexant6.7.2020 07:00:00 CESTPress release

Results confirm and reinforce the efficacy and safety profile from the first pivotal studyCompany targets filing the New Drug Application (NDA) around the end of 2020Idorsia to host an investor webcast to discuss the second Phase 3 results today at 14:00hrs CEST Allschwil, Switzerland – July 6, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the second pivotal Phase 3 study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant, in 924 adult and elderly patients (39.3% ≥ 65 years) with insomnia. The study confirms the findings of the first pivotal study, demonstrating efficacy of treatment with daridorexant on objective and subjective sleep parameters and showed positive effects on daytime functioning, with patients reporting no morning sleepiness and no evidence of rebound or withdrawal symptoms upon treatment discontinuation. On April 20, 2020, the company reported (media release) the results of the first pivotal study with dar

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids6.7.2020 07:00:00 CESTPress release

PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and continued safety of linzagolix at week 52 Results confirm linzagolix as a potential best-in-class GnRH antagonist, with a pooled responder rate of 84.7% for the 200 mg with Add Back Therapy* (ABT) dose from PRIMROSE 1 and 2 Linzagolix is the only GnRH antagonist as a potential unique treatment option for up to 50% of US women with uterine fibroids for whom ABT therapy may be contraindicated Success of PRIMROSE 1 and 2 studies enables progression towards regulatory submissions, anticipated 4Q 2020 in the EU and 1H 2021 in the US GENEVA, Switzerland and BOSTON, MA (July 6, 2020) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced top-line results from the PRIMROSE 1 and 2 studies of Ysel

Airtel deploys India’s largest open cloud-based VoLTE network with Nokia software products6.7.2020 07:00:00 CESTPress release

Press Release FINAL Airtel deploys India’s largest open cloud-based VoLTE network with Nokia software products ·As part of its cloudification strategy, Airtel will deploy Nokia’s CloudBand Infrastructure Software 6 July 2020 Espoo, Finland – Nokia today announced that its CloudBand-based software products are powering Bharti Airtel’s (“Airtel”) Voice over LTE (VoLTE) network in India. The network supports over 110 million customers, making it the largest cloud-based VoLTE network in India and the largest Nokia-run VoLTE in the world. The cloud-based VoLTE deployment allows Airtel to provide its mobile customers faster and more reliable, cost-efficient call connectivity. The solution, which has been deployed to cover all 22 telecom service areas in India, uses Commercial Off-the-Shelf IT hardware with cloud-based Virtual Network Functions (VNFs), which consumes much less power and space compared to the traditional 2G/3G Circuit Switched legacy core. Nokia’s VoLTE solution enables Airtel

DIAC S.A.: UPDATE OF NEU MTN PROGRAMME3.7.2020 19:32:13 CESTPress release

July, 3rd 2020 DIAC S.A.: UPDATE OF NEU MTN PROGRAMME DIAC S.A. updated the Information Memorandum of its Negotiable Medium Term Notes (NEU MTN Programme). This documentation was approved by the Banque de France is available on its website under the following link: https://eucpmtn.banque-france.fr/public/#/liste-des-emetteurs/5f8b9dec-b611-ea11-80f7-001dd8b71ea9 DIAC S.A. Etablissement de crédit et intermédiaire d’assurances, au capital de 659 334 050 EUR. Siège social : 14, avenue du Pavé Neuf – 93168 Noisy-le-Grand cedex SIREN 702 002 221 RCS Bobigny – N° TVA : FR02 702002221 – Code APE 6492Z – N° ORIAS : 07 004 966 – www.orias.fr Attachment Update DIAC programme NEU MTN 2020

Maha Energy AB (publ) Announce June Production Volumes3.7.2020 17:13:36 CESTPress release

­­­Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm July 3, 2020 Maha Energy AB (publ) Announce June Production Volumes Production Volumes The Company's aggregate sales production for the month of June totaled 112,1511 barrels of oil and 57.090 million scf of gas for a combined average production of approximately 4,056 BOE/day2, before royalties and taxes. Other than some minor unplanned shutdowns, production continues to be affected by the impact of the Covid-19 pandemic. 1 Subject to minor standard industry adjustments at the time of custody transfer. 2 Barrels of oil equivalent ("BOE") conversion ratio of 6,000 scf: 1 bbl is used. For more information, please contact: Jonas Lindvall (CEO) Tel: +46 8 611 05 11 Email: jonas@mahaenergy.ca or Victoria Berg (Investor Relations) Tel: +46 8 611 05 11 Email: victoria@mahaenergy.ca Maha in Brief Maha Energy AB is a Swedish public limited liability company. FNCA Sweden AB has been engaged as C

Norsk Hydro: Production resumed at Paragominas and Alunorte3.7.2020 17:00:00 CESTPress release

The power supply to Hydro’s Paragominas bauxite mine, in the state of Pará in northern Brazil, has been restored, allowing production to restart. As a result, production is being ramped up at Hydro’s Alunorte alumina refinery. On June 20, three power transmission towers overturned, cutting the power supply to the mine and temporarily halting production. The transmission towers have been repaired, and the power has been restored. There were no personnel injuries, damage to other production assets or impact on the nearby environment related to the power outage. The company is cooperating with local authorities to determine the cause of the incident. Preliminary findings indicate that parts were stolen from the towers causing them to overturn. Investor contact: Line Haugetraa +47 41406376 Line.Haugetraa@hydro.com Media contact: Anders Vindegg +47 93864271 Anders.Vindegg@hydro.com